Compare MRNA & CTAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | CTAS |
|---|---|---|
| Founded | 2010 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2B | 88.8B |
| IPO Year | 2018 | 1994 |
| Metric | MRNA | CTAS |
|---|---|---|
| Price | $199.18 | $218.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 20 |
| Target Price | $164.53 | ★ $218.44 |
| AVG Volume (30 Days) | ★ 11.4M | 1.7M |
| Earning Date | 11-06-2026 | 12-17-2026 |
| Dividend Yield | N/A | ★ 0.94% |
| EPS Growth | ★ 21.77 | 11.59 |
| EPS | N/A | ★ 1.36 |
| Revenue | ★ $19,263,000,000.00 | $6,892,303,000.00 |
| Revenue This Year | $24.09 | $8.71 |
| Revenue Next Year | $11.33 | $7.53 |
| P/E Ratio | ★ N/A | $163.51 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $161.16 |
| 52 Week High | $280.80 | $233.46 |
| Indicator | MRNA | CTAS |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 49.68 |
| Support Level | $181.02 | $193.82 |
| Resistance Level | $254.48 | $226.69 |
| Average True Range (ATR) | 17.92 | 4.86 |
| MACD | -7.14 | -1.29 |
| Stochastic Oscillator | 11.39 | 14.93 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Cintas has roots dating back to 1929, when the Farmer family cleaned and resold dirty rags to manufacturing plants in Ohio. The firm has expanded its business organically and through acquisitions, and today Cintas acts as a one-stop outsourcing partner for businesses. Cintas will design, manufacture, collect, and clean every employee uniform for a small weekly sum, taking on the upfront capital expense itself. At the same stop, Cintas can also replace soiled or depleted mats, mops, trash liners, towels, first aid supplies, fire extinguishers, and cleaning products. Businesses value an outsourcing partner like Cintas as it simplifies operations and leaves noncore tasks with high regulatory standards in the hands of professionals.